J. Goldman & Co LP Invests $1.14 Million in Rezolute, Inc. (NASDAQ:RZLT)

J. Goldman & Co LP bought a new position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 232,627 shares of the company's stock, valued at approximately $1,140,000. J. Goldman & Co LP owned about 0.40% of Rezolute at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RZLT. Jacobs Levy Equity Management Inc. increased its holdings in Rezolute by 41.9% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 69,989 shares of the company's stock worth $343,000 after buying an additional 20,667 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Rezolute in the fourth quarter worth approximately $168,000. Ameriprise Financial Inc. acquired a new position in shares of Rezolute during the 4th quarter worth $342,000. 683 Capital Management LLC bought a new position in shares of Rezolute during the 4th quarter valued at $630,000. Finally, Nantahala Capital Management LLC raised its holdings in shares of Rezolute by 10.9% during the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after purchasing an additional 280,861 shares in the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Trading Up 2.0%

NASDAQ:RZLT traded up $0.07 during mid-day trading on Thursday, hitting $3.56. 714,164 shares of the company's stock traded hands, compared to its average volume of 622,628. The firm has a 50 day moving average of $3.24 and a two-hundred day moving average of $4.34. Rezolute, Inc. has a 12 month low of $2.22 and a 12 month high of $6.19. The firm has a market capitalization of $215.50 million, a price-to-earnings ratio of -2.92 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). As a group, equities research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Insider Activity at Rezolute

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the purchase, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. This trade represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wladimir Hogenhuis acquired 10,000 shares of Rezolute stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now directly owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 39,060 shares of company stock worth $130,694 in the last 90 days. 18.39% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

RZLT has been the subject of a number of recent research reports. JMP Securities upped their price objective on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a report on Thursday, February 13th. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Rezolute in a report on Monday, April 28th. Guggenheim reissued a "buy" rating on shares of Rezolute in a research note on Monday, February 10th. Craig Hallum raised Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Finally, Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a research report on Wednesday. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $12.14.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.